BLLNBillionToOne, Inc.
$98.15
$98.15
$64.0352 weeks$149.76
The financials
BillionToOne, Inc. by the numbers
BillionToOne, Inc. (BLLN) reported revenue of $109M in Q2 2026 (quarter ended Jun 30, 2026), up 64% from the same quarter a year earlier. That came with a gross margin of 70% and net income of $8.1M (7.4% of revenue). For the full year FY2025, revenue was $305M (+100% year on year) and net income $7.5M. Its largest product in Q2 2026 was Prenatal at $94M, 86% of the disclosed total, well ahead of Oncology at 12%. The next results filing is expected around Nov 4, 2026, a quarter after the last one.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $109M | $67M | +64% |
| Gross profit | $77M | $43M | +77% |
| Operating income | $5.5M | −$1.6M | to a profit |
| Net income | $8.1M | −$246K | to a profit |
| Diluted EPS | $0.15 | −$0.02 | to a profit |
| Product | Revenue | Share |
|---|---|---|
| Prenatal | $94M | 86% |
| Oncology | $14M | 12% |
| Clinical Trial Support And Other Services | $1.5M | 1.4% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $109.4M (+0.98%)
Oncology grew +176% year on yearPrenatal +55% year on year
Segment Latestquarter on quarteryear on year
- Prenatal$94.2M$94.2Mquarter on quarter -2.4%year on year +55%-2.4%+55%
- Oncology$13.7M$13.7Mquarter on quarter +27%year on year +176%+27%+176%
- Clinical Trial Support And Other Services$1.5M$1.5Mquarter on quarter +34%year on year +99%+34%+99%
Diagnostics & Research
The closest names by size in the same industry